Moderna (NASDAQ:MRNA) shares gained more than 6% intra-day today after the company revealed its projection of generating $10 billion to $15 billion in annual sales from new drugs by 2028.

In addition to this, the drugmaker expects to achieve $8 billion to $15 billion in sales from the respiratory franchise by 2027, as previously announced. Moderna also anticipates COVID-19 vaccine sales ranging from $6 billion to $8 billion in 2023, with specific figures contingent on U.S. vaccination rates.

Furthermore, the company reported the successful outcome of its Phase 3 trial for the flu vaccine mRNA-1010.